Q4 2020 13F Holders as of 12/31/2020
-
Type / Class
-
Equity / Common Stock, $0.01 par value per share
-
Shares outstanding
-
107M
-
Number of holders
-
169
-
Total 13F shares, excl. options
-
61.9M
-
Shares change
-
+6.77M
-
Total reported value, excl. options
-
$3.39B
-
Value change
-
+$435M
-
Put/Call ratio
-
1.59
-
Number of buys
-
101
-
Number of sells
-
-52
-
Price
-
$54.84
Significant Holders of ROCKET PHARMACEUTICALS, INC. - Common Stock, $0.01 par value per share (RCKT) as of Q4 2020
183 filings reported holding RCKT - ROCKET PHARMACEUTICALS, INC. - Common Stock, $0.01 par value per share as of Q4 2020.
ROCKET PHARMACEUTICALS, INC. - Common Stock, $0.01 par value per share (RCKT) has 169 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 61.9M shares
of 107M outstanding shares and own 57.73% of the company stock.
Largest 10 shareholders include RTW INVESTMENTS, LP (17.1M shares), PRICE T ROWE ASSOCIATES INC /MD/ (3.48M shares), PERCEPTIVE ADVISORS LLC (3.4M shares), BlackRock Inc. (2.97M shares), TANG CAPITAL MANAGEMENT LLC (2.97M shares), WELLINGTON MANAGEMENT GROUP LLP (2.68M shares), RA CAPITAL MANAGEMENT, L.P. (2.14M shares), VANGUARD GROUP INC (2.04M shares), WESTFIELD CAPITAL MANAGEMENT CO LP (1.59M shares), and LORD, ABBETT & CO. LLC (1.59M shares).
This table shows the top 169 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.